SLUG Lentiviral Activation Particles (h): sc-400389-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- SLUG Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- SLUG Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by SLUG Lentiviral Activation Plasmid (h) and SLUG Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the SNAI2 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: SLUG Antibody (A-7): sc-166476
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SLUG Lentiviral Activation Particles (h) | sc-400389-LAC | 200 µl | $455.00 |
Human SNAI2 encodes the zinc-finger transcription factor SLUG, a key regulator of epithelial–mesenchymal transition (EMT) that represses epithelial gene programs and promotes motility, invasion-associated phenotypes, and survival under stress. SLUG integrates signals from developmental and stress-response pathways, including TGF-β, WNT/β-catenin, NOTCH, RTK/MAPK, and hypoxia-responsive networks, to rewire transcriptional states and cell fate decisions. Its activity influences cytoskeletal remodeling, adhesion dynamics, and lineage plasticity, and altered SNAI2 regulation is frequently studied in contexts of tumor progression, metastasis biology, and therapy resistance mechanisms. SLUG also has roles in stem/progenitor cell behavior and differentiation programs, making it relevant to models of tissue remodeling and microenvironment-driven phenotypic switching.
SLUG Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient SNAI2 upregulation across a broader range of human cell types.
SLUG Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the SNAI2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous SLUG expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native SNAI2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.